Kite Pharma, Inc. is a privately held development stage biotechnology company engaged in the design and development of pioneering immune-based targeted therapies for multiple cancer indications. Kite is advancing a portfolio of proprietary product candidates designed to leverage and enhance the patient's own immune system to fight tumor cells. These novel personalized immunotherapies, which capitalize on the selectivity and potency of immune cells, are aimed at providing significant and durable clinical benefit in a wide range of tumor indications.
Kite's management team has a proven track record of building successful biotechnology companies and developing cutting edge immunotherapies and oncology treatments. Additionally, the company's Scientific Advisory Board is comprised of leaders who have discovered and guided the advancement of key novel immunotherapies.